C-GHJXcell therapy, lymph node bioreactors, organ regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Treat end-stage liver disease by growing functional ectopic liver tissue using lymph nodes as bioreactors.
Allogeneic hepatocyte transplantation into periduodenal lymph nodes via endoscopic ultrasound in a Phase 2a dose-escalation trial assessing safety, tolerability, and efficacy.
Phase 2a clinical trial with first patient dosed.
Address renal disease by using lymph nodes as bioreactors to grow functioning ectopic kidney tissue.
Cell therapy program based on engraftment, proliferation, and formation of functional ectopic organs in lymph nodes.
Listed in LyGenesis pipeline.
Develop allogeneic cell therapies that transform lymph nodes into bioreactors capable of growing functioning ectopic organs that recapitulate native organ function.
Allogeneic cell therapies engrafted into lymph nodes, where cells proliferate and form functional ectopic organs.
Platform described as supporting programs in liver, pancreas, kidneys, and thymus.
Address Type 1 diabetes by using lymph nodes as bioreactors to grow functioning ectopic pancreatic tissue.
Cell therapy program based on engraftment, proliferation, and formation of functional ectopic organs in lymph nodes.
Listed in LyGenesis pipeline.
Address thymus aging and autoimmune disorders by using lymph nodes as bioreactors to grow functioning ectopic thymus tissue.
Cell therapy program based on engraftment, proliferation, and formation of functional ectopic organs in lymph nodes.
Listed in LyGenesis pipeline.